Cadence Pharmaceuticals News (NASDAQ:CADX)
| Latest Cadence Pharmaceuticals News Headlines | | Date | Time | Source | | | 06/17/2008 | 4:30PM | PRNUS | Cadence Pharmaceuticals' CEO Theodore Schroeder to Present at the Leerink Swann Pain Roundtable Conference on June 23, 2008 in N
SAN DIEGO, June 17 /PRNewswire-FirstCall/ -- Cadence Pharmaceuticals, Inc. (NASDAQ:CADX), a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting, announced today that the company's President and CEO Theodore Schroeder... More...>> |
| 06/04/2008 | 4:36PM | PRNUS | Cadence Pharmaceuticals' CEO Theodore Schroeder to Present at the Seventh Annual Needham & Company, LLC Biotechnology and Medica
SAN DIEGO, June 4 /PRNewswire-FirstCall/ -- Cadence Pharmaceuticals, Inc. (NASDAQ:CADX), a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting, announced today that the company's President and CEO Theodore Schroeder... More...>> |
| 05/06/2008 | 8:00AM | PRNUS | Cadence Pharmaceuticals Reports First Quarter 2008 Financial Results and Provides Clinical Program Update
Phase III Clinical Trial of Acetavance(TM) for the Treatment of Fever Achieves Primary Endpoint
SAN DIEGO, May 6 /PRNewswire-FirstCall/ -- Cadence Pharmaceuticals, Inc. (NASDAQ:CADX), a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use... More...>> |
| 04/30/2008 | 5:06PM | PRNUS | Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss First Quarter Financial Results and Provide a Clinical Pr
SAN DIEGO, April 30 /PRNewswire-FirstCall/ -- Cadence Pharmaceuticals, Inc. (NASDAQ:CADX), a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting, today announced that it will release its first quarter financial results... More...>> |
| 04/30/2008 | 4:57PM | PRNUS | Cadence Pharmaceuticals' CEO Ted Schroeder to Present at Three Investment Conferences During the Month of May 2008
SAN DIEGO, April 30 /PRNewswire-FirstCall/ -- Cadence Pharmaceuticals, Inc. (NASDAQ:CADX), a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting, announced today that the company's President and CEO Theodore Schroeder... More...>> |
| 03/13/2008 | 7:00PM | PRNUS | Cadence Pharmaceuticals to Present at the Cowen and Company 28th Annual Health Care Conference on March 20, 2008 in Boston
SAN DIEGO, March 13 /PRNewswire-FirstCall/ -- Cadence Pharmaceuticals, Inc. (NASDAQ:CADX), a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting, announced today that Senior Vice President and CFO William R. LaRue... More...>> |
| 03/12/2008 | 4:01PM | PRNUS | Cadence Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Financial Results and Provides Corporate and Clinical Program
SAN DIEGO, March 12 /PRNewswire-FirstCall/ -- Cadence Pharmaceuticals, Inc. (NASDAQ:CADX), a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting, today reported financial results for the quarter and year ended December... More...>> |
| 03/06/2008 | 8:49PM | PRNUS | Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2007 Financial Results and C
SAN DIEGO, March 6 /PRNewswire-FirstCall/ -- Cadence Pharmaceuticals, Inc. (NASDAQ:CADX), a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting, today announced that it will release its fourth quarter and full year... More...>> |
| 02/20/2008 | 5:01PM | PRNUS | Cadence Pharmaceuticals Completes $49.3 Million Registered Direct Offering
SAN DIEGO, Feb. 20 /PRNewswire-FirstCall/ -- Cadence Pharmaceuticals, Inc. (NASDAQ:CADX), a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting, today announced that it completed its previously announced registered... More...>> |
| 02/15/2008 | 8:00AM | PRNUS | Cadence Pharmaceuticals to Raise up to $49.3 Million in Registered Direct Common Stock Offering
SAN DIEGO, Feb. 15 /PRNewswire-FirstCall/ -- Cadence Pharmaceuticals, Inc. (NASDAQ:CADX) a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting, announced today that Cadence has received commitments from selected... More...>> |
| 01/31/2008 | 8:30PM | PRNUS | Cadence Pharmaceuticals' CEO Theodore Schroeder to Present at Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Devic
SAN DIEGO, Jan. 31 /PRNewswire-FirstCall/ -- Cadence Pharmaceuticals, Inc. (NASDAQ:CADX), a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting, announced today that the company's President and CEO Theodore Schroeder... More...>> |
| 01/11/2008 | 7:30AM | PRNUS | Cadence Pharmaceuticals Announces Topline Results of Two Phase III Clinical Trials of Acetavance(TM)
SAN DIEGO, Jan. 11 /PRNewswire-FirstCall/ -- Cadence Pharmaceuticals, Inc. (NASDAQ:CADX) today announced top line results of two of the company's four pivotal, Phase III clinical trials of Acetavance(TM), a formulation of acetaminophen for intravenous use. One of these clinical trials did not meet its primary endpoint... More...>> |
| 11/14/2007 | 4:30PM | PRNUS | Cadence Pharmaceuticals Reports Third Quarter 2007 Financial Results and Provides Clinical Program Update
SAN DIEGO, Nov. 14 /PRNewswire-FirstCall/ -- Cadence Pharmaceuticals, Inc. (NASDAQ:CADX), a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting, today reported unaudited financial results for the third quarter and... More...>> |
| 11/09/2007 | 9:15AM | PRNUS | Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Third Quarter 2007 Financial Results
SAN DIEGO, Nov. 9 /PRNewswire-FirstCall/ -- Cadence Pharmaceuticals, Inc. (NASDAQ:CADX), a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting, today announced that it will release its third quarter ended September... More...>> |
| 11/08/2007 | 8:58PM | PRNUS | Cadence Pharmaceuticals' Chief Medical Officer James Breitmeyer to Present at JMP Securities Healthcare Focus Conference
SAN DIEGO, Nov. 8 /PRNewswire-FirstCall/ -- Cadence Pharmaceuticals, Inc. (NASDAQ:CADX), a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting, announced today that the company's Executive Vice President and Chief... More...>> |
| 10/26/2007 | 6:00AM | PRNUS | Cadence Pharmaceuticals' CEO Theodore Schroeder to Present at BIOCOM Investor Conference 2007
SAN DIEGO, Oct. 26 /PRNewswire-FirstCall/ -- Cadence Pharmaceuticals, Inc. (NASDAQ:CADX), a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting, announced today that the company's President and CEO Theodore Schroeder... More...>> |
| 10/03/2007 | 4:30PM | PRNUS | Cadence Pharmaceuticals' CEO Theodore Schroeder to Present at BIO Investor Forum
SAN DIEGO, Oct. 3 /PRNewswire-FirstCall/ -- Cadence Pharmaceuticals, Inc. (NASDAQ:CADX), a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting, announced today that the company's President and CEO Theodore Schroeder... More...>> |
| 09/20/2007 | 9:00AM | PRNUS | Cadence Pharmaceuticals' CEO Theodore Schroeder to Present at UBS 2007 Global Life Sciences Conference
SAN DIEGO, Sept. 20 /PRNewswire-FirstCall/ -- Cadence Pharmaceuticals, Inc. (NASDAQ:CADX), a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting, announced today that the company's President and CEO Theodore Schroeder... More...>> |
| 09/13/2007 | 5:00PM | PRNUS | Cadence Pharmaceuticals Names Malvina Laudicina Vice President of Regulatory Affairs and Quality Assurance
SAN DIEGO, Sept. 13 /PRNewswire-FirstCall/ -- Cadence Pharmaceuticals, Inc. (NASDAQ:CADX), a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting, announced today that Malvina Laudicina has joined Cadence's management... More...>> |
| 08/30/2007 | 6:00AM | PRNUS | Cadence Pharmaceuticals Completes Enrollment of Pivotal Phase III Trial for Intravenous Acetaminophen Ahead of Schedule
SAN DIEGO, Aug. 30 /PRNewswire-FirstCall/ -- Cadence Pharmaceuticals, Inc. (NASDAQ:CADX), a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting, today announced it has completed patient enrollment in a pivotal Phase... More...>> |
|
|
|